Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2019 | Utilizing health resources

Karthik Ramasamy • 24 Mar 2019
EBMT 2019
General Multiple Myeloma

Karthik Ramasamy, PhD, of Oxford University Hospitals, Oxford, UK, discusses the utilization of health resources. Dr Ramasamy was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany

More from Karthik Ramasamy

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS
1:34
Monoclonal light chain glycosylation is associated with evolution of incidental MGUS
Karthik Ramasamy • 7 Dec 2025
RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma
1:23
RADAR trial: Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed ultra-high-risk myeloma
Karthik Ramasamy • 7 Dec 2025
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial
1:55
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial
Karthik Ramasamy • 15 Sep 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Karthik Ramasamy • 18 Dec 2025
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Karthik Ramasamy • 7 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Karthik Ramasamy • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Karthik Ramasamy • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals